In lung cancer, a pilot study has shown that serum PCSK9 levels at the second nivolumab cycle could predict overall survival (OS) in elderly patients with non-small cell lung cancer (NSCLC): low levels of circulating PCSK9 predicted better OS in elderly patients with advanced, pretreated NSCLC (8). The gene discussed is PCSK9; the disease is lung carcinoma.